Barclays analyst Matt Miksic lowered the firm’s price target on Tandem Diabetes to $71 from $76 and keeps an Overweight rating on the shares. The company delivered Q4 results inline with the pre-release and ahead of consensus, and sales guidance was inline, the analyst tells investors in a research note. The firm continues to view Tandem’s 2023 sales outlook as "achievable if not beatable."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on TNDM:
- 3 Stocks to Buy Today, 2/24/2023, According to Top Analysts
- Tandem Diabetes sees FY23 revenue $885M-$900M, consensus $891.6M
- Tandem Diabetes reports Q4 EPS (25c), consensus (6c)
- Tandem Diabetes names Rebecca Robertson as new board chair
- Tandem Diabetes initiated with a Peer Perform at Wolfe Research